RLAY · Relay Therapeutics, Inc.
$19.39
+0.43 (+2.27%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$3.83B
Shares
219.14M
Volume · Oct 5
2.94M
Avg daily vol (3M)
2.84M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.39
Open$19.00
Day$18.29–19.40
52W close$5.59–20.75
Avg vol 30d3.3M
Short int44.5M · 20.3% float · 14.2d
Short vol51%
Last earningsAug 6, 2026
DataJul 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
May 17, 2027
Est · unconfirmed
· in 32 wks
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+263.2%
Trailing year
Short interest
20.3%
Latest settlement · 14.2 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Relay Therapeutics reported Q2 2026 results with progress across its zovegalisib program: selected the zovegalisib plus atirmociclib triplet as the go-forward 1L breast cancer regimen (Phase 3 expected to start early 2027), presented initial positive Phase 1/2 vascular anomalies data, and raised cash to approximately $911 million providing runway into 2029; R&D spend rose to $76.5M driving a wider net loss of $83.7M.
Bullish
- + Selected zovegalisib + atirmociclib triplet for 1L breast cancer with Phase 3 expected to initiate early 2027, with Pfizer supplying atirmociclib while Relay retains full global rights to zovegalisib.
- + Reported 44% ORR for the triplet in heavily pretreated (median 3L) HR+/HER2- breast cancer patients at unoptimized doses, with consistent safety profile.
- + Presented initial positive Phase 1/2 ReInspire data in vascular anomalies with 60% volumetric response at 12 weeks, supporting potential chronic use.
- + Cash position grew to approximately $911M (from $642.1M at March 31, 2026) following a $316M follow-on offering, expected to fund operations into 2029.
- + 11-month PFS shown for the doublet in 2L HR+/HER2- breast cancer, viewed by management as meaningfully differentiated versus capivasertib's ~5.5 months, with Phase 3 ReDiscover-2 enrolling.
Bearish
- − R&D expenses rose to $76.5M in Q2 2026 from $63.9M in Q2 2025, driving a wider net loss of $83.7M.
- − Net loss widened to $83.7M in Q2 2026 from $70.4M in Q2 2025.
- − Revenue declined to $0.4M in Q2 2026 from $0.7M in Q2 2025.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+38%
above
Price vs 50-day avg
+1%
above
RSI (14)
56
neutral
MACD trend
Positive
52-week position
91%
near high
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+31%
trailing
YTD return
+129%
this year
Relative strength
+20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
2 of 262 funds reported for Sep 30 · net +81 sh shares · +1 new
Insider flow
Distributing
Net -$116.5M over 90 days · 100% sells
Short interest
Rising
20.30% of float · ▲ +2.2% MoM · 14.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
262 holders — near 3-yr high, broad support
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
+53%
Y/Y
EPS growth
+32%
Y/Y
Free cash flow
$-235.9M
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+38%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
56
Neutral
MACD trend
Positive
Bullish
52-week position
91%
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $19 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
2 of 262 funds reported for Sep 30 · net +81 sh shares · +1 new
Insider flow
Distributing
Net -$116.5M over 90 days · 100% sells
Short interest
Rising
20.30% of float · ▲ +2.2% MoM · 14.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
262 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $19 · 91%
Range high $21
vs 200-day avg +38%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross proceeds from underwritten follow-on public offering | $316M | May 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RLAY
this stock
Relay Therapeutics, Inc.
|
$3.83B | +129.2% | +53.4% | — | 20.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RLAY | +9.6% | +1.8% | +31.5% | +7.4% | +129.2% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +8.4% | +1.2% | +19.9% | +5.8% | +115.6% |